302 results on '"Pollock, Pamela M"'
Search Results
52. The CDKN2A (p16) Gene and Human Cancer
53. Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk
54. Melanoma: Cellular and Molecular Abnormalities
55. Notch and NOXA-Related Pathways in Melanoma Cells
56. Cancer: Lucky draw in the gene raffle
57. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
58. FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models
59. Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer
60. Potential Synergy
61. A genome-based strategy uncovers frequent BRAF mutations in melanoma
62. FGFR inhibition in endometrial cancer induces caspase-independent cell death that can be augmented with ABT-737
63. Abstract LB-B31: FGFR inhibition in endometrial cancer induces caspase-independent cell death that can be augmented with ABT-737
64. hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases
65. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
66. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
67. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation
68. Abstract 1093: The melanoma-enriched microRNA miR-4731 regulates genes involved in cell cycle and the melanosome
69. The ‘melanoma-enriched’ microRNA miR-4731-5p acts as a tumour suppressor
70. A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding
71. Abstract B114: Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines
72. The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis
73. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
74. Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents
75. ‘Healthy mobile check-ins’ study: Using GIS in smartphones to track use of urban environment by survivors of endometrial cancer
76. XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts
77. Lineage-Specific Biomarkers Predict Response to FGFR Inhibition
78. Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
79. Fibroblast Growth Factor Receptor Inhibition Synergizes With Paclitaxel and Doxorubicin in Endometrial Cancer Cells
80. FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
81. Cellular Settings Mediating Src Substrate Switching between Focal Adhesion Kinase Tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) Tyrosine 734
82. Abstract 4733: Activating FGFR2 kinase domain mutations provide resistance to dovitinib (TKI258)
83. FGFR2 mutations are rare across histologic subtypes of ovarian cancer
84. A genome-based strategy uncovers frequent BRAF mutations in melanoma
85. Lucky draw in the gene raffle
86. Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines
87. Abstract C86: FGFR inhibition potentiates the effect of conventional chemotherapeutic agents in endometrial cancer cells
88. Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix
89. Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
90. FGFR2 as a molecular target in endometrial cancer
91. Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
92. Mutation analysis of the CDKN2A promoter in Australian melanoma families
93. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development
94. CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin
95. Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation
96. Melanoma: Genetics
97. Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
98. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas
99. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families : evidence for common founders and independent mutations
100. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.